Infection prevention company Tristel plc (AIM: TSTL) announced on Monday that it has commercially launched 3T Pro, a premium tier of its 3T digital compliance platform, marking the first paid version of the platform as the company seeks to build recurring digital revenue alongside its infection prevention products.
Previously offered free of charge, the 3T platform supports healthcare providers with staff training management and compliance tracking. Developed by Tristel's in-house software team, 3T Pro adds enhanced asset tracking and lifecycle management, advanced dashboards, structured audit reporting and a scalable data architecture to support future integrations.
The launch introduces a three-tier structure comprising a free entry-level version, a mid-tier combining training management with device traceability, and the premium 3T Pro offering advanced customisation, workflows, reporting and audit readiness. Existing users of traceability features will receive transitional licensing arrangements, while the free entry-level tier will remain available to encourage broad adoption across the healthcare sector.
Oxurion in talks to acquire Eclevar's MedTech CRO business and assets
FDA Advisory Committee votes in favour of GRAIL's Galleri multi-cancer early detection test
Insmed's ARIKAYCE sNDA granted priority review by FDA
ProBio and Kun Tuo collaborate to deliver integrated CDMO-CRO solutions for advanced therapies
Myosin Therapeutics chosen for 2026-2027 NCI Investor Initiatives Showcase
Medtronic receives FDA clearance for LigaSure RAS Maryland instrument on Hugo system
Aptar and Aceso Therapeutics partner to advance inhaled cystic fibrosis therapy
Immuron signs US distribution deal for PROIBS
Tempus announces receipt of FDA clearance for AI pulmonary hypertension detection product
Pulnovo Medical commences enrolment in PULSE-LHD IDE clinical trial
Implantica's RefluxStop receives US FDA approval
Sectra to provide Education Portal to Loyalist College for medical imaging training
Aqua Medical treats second type 2 diabetes patient in IDE trial of investigational PIMA procedure
Abbott and NACHC launch nationwide Food for Health initiative
Galmed reports positive preclinical results for Aramchol in prostate cancer